CN102405285B - Foxm1肽及包含它的疫苗 - Google Patents

Foxm1肽及包含它的疫苗 Download PDF

Info

Publication number
CN102405285B
CN102405285B CN201080017145.2A CN201080017145A CN102405285B CN 102405285 B CN102405285 B CN 102405285B CN 201080017145 A CN201080017145 A CN 201080017145A CN 102405285 B CN102405285 B CN 102405285B
Authority
CN
China
Prior art keywords
cancer
peptide
foxm1
peptides
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080017145.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102405285A (zh
Inventor
角田卓也
大泽龙司
吉村祥子
渡边朝久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN102405285A publication Critical patent/CN102405285A/zh
Application granted granted Critical
Publication of CN102405285B publication Critical patent/CN102405285B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201080017145.2A 2009-02-18 2010-02-17 Foxm1肽及包含它的疫苗 Active CN102405285B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15340809P 2009-02-18 2009-02-18
US61/153,408 2009-02-18
PCT/JP2010/001005 WO2010095428A1 (en) 2009-02-18 2010-02-17 Foxm1 peptides and vaccines containing the same

Publications (2)

Publication Number Publication Date
CN102405285A CN102405285A (zh) 2012-04-04
CN102405285B true CN102405285B (zh) 2015-04-22

Family

ID=42633716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080017145.2A Active CN102405285B (zh) 2009-02-18 2010-02-17 Foxm1肽及包含它的疫苗

Country Status (15)

Country Link
US (1) US8617562B2 (enExample)
EP (1) EP2408912B1 (enExample)
JP (1) JP5728717B2 (enExample)
KR (1) KR101713586B1 (enExample)
CN (1) CN102405285B (enExample)
BR (1) BRPI1008887A2 (enExample)
CA (1) CA2752560C (enExample)
DK (1) DK2408912T3 (enExample)
ES (1) ES2618896T3 (enExample)
IL (1) IL214435A0 (enExample)
MX (1) MX2011008763A (enExample)
RU (1) RU2560431C2 (enExample)
SG (1) SG173751A1 (enExample)
TW (1) TWI469791B (enExample)
WO (1) WO2010095428A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108117584B (zh) 2007-08-20 2021-08-24 肿瘤疗法科学股份有限公司 Foxm1肽和包含foxm1肽的药剂
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
GB201410686D0 (en) * 2014-06-16 2014-07-30 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3360886B1 (en) * 2015-10-08 2023-01-25 Oncotherapy Science, Inc. Foxm1-derived peptide, and vaccine including same
CN105524159B (zh) * 2015-11-16 2021-04-09 西南交通大学 具有癌细胞选择性杀伤和迁移抑制作用的多肽分子与用途
CN105999227B (zh) * 2016-08-12 2019-08-06 湖南大学 FOXM1蛋白氮端（1-234 aa）的表达及其用途
JP2020503840A (ja) 2016-10-07 2020-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用
CN111787930B (zh) * 2017-10-06 2024-12-20 芝加哥大学 针对癌症特异性抗原对t淋巴细胞的筛选
HRP20230007T1 (hr) * 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
CN109055327B (zh) * 2018-07-23 2021-04-06 浙江工业大学 醛酮还原酶突变体及其应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN114591400B (zh) * 2022-03-29 2022-10-21 西南交通大学 一组靶向FoxM1-DBD多肽及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549771A2 (en) * 2002-09-30 2005-07-06 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
CN1977052A (zh) * 2004-03-23 2007-06-06 肿瘤疗法科学股份有限公司 用于诊断非小细胞肺癌的方法
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
EP0846761A1 (en) * 1996-12-09 1998-06-10 Introgene B.V. A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
ES2294844T3 (es) 1998-06-25 2008-04-01 Green Peptide Co., Ltd. Peptidos antigenicos tumorales derivados de ciclofilina b.
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2448881A1 (en) 2001-06-04 2002-12-12 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants ii
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2469274A1 (en) 2001-12-10 2003-06-19 Kyogo Itoh Tumor antigens
US20040109844A1 (en) * 2002-08-28 2004-06-10 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
WO2005090991A1 (en) 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
JP4579246B2 (ja) 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
ES2616337T3 (es) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
WO2005076979A2 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2006141208A (ja) 2004-11-16 2006-06-08 Univ Of Tokushima 多発性骨髄腫、白血病、悪性リンパ腫、肺癌等の免疫療法剤
EP2295601A1 (en) 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
WO2007013665A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
EP2018440A1 (en) 2006-04-20 2009-01-28 Oncotherapy Science, Inc. NMU-GHSR1b/NTSR1 ONCOGENIC SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR LUNG CANCER
CN108117584B (zh) * 2007-08-20 2021-08-24 肿瘤疗法科学股份有限公司 Foxm1肽和包含foxm1肽的药剂
MX2010002001A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.
BRPI1009301A2 (pt) 2009-03-18 2016-03-08 Oncotherapy Science Inc peptídeos neil 3 e vacinas incluindo os mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549771A2 (en) * 2002-09-30 2005-07-06 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
CN1977052A (zh) * 2004-03-23 2007-06-06 肿瘤疗法科学股份有限公司 用于诊断非小细胞肺癌的方法
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer

Also Published As

Publication number Publication date
EP2408912A4 (en) 2013-04-17
MX2011008763A (es) 2011-09-09
TW201032821A (en) 2010-09-16
KR20110117241A (ko) 2011-10-26
ES2618896T3 (es) 2017-06-22
RU2560431C2 (ru) 2015-08-20
WO2010095428A1 (en) 2010-08-26
US20120156231A1 (en) 2012-06-21
CN102405285A (zh) 2012-04-04
CA2752560A1 (en) 2010-08-26
RU2011138160A (ru) 2013-03-27
EP2408912B1 (en) 2017-01-18
KR101713586B1 (ko) 2017-03-08
CA2752560C (en) 2017-01-24
BRPI1008887A2 (pt) 2016-03-01
JP5728717B2 (ja) 2015-06-03
IL214435A0 (en) 2011-09-27
AU2010216980A1 (en) 2011-08-25
EP2408912A1 (en) 2012-01-25
TWI469791B (zh) 2015-01-21
JP2012517799A (ja) 2012-08-09
SG173751A1 (en) 2011-09-29
US8617562B2 (en) 2013-12-31
DK2408912T3 (en) 2017-03-20

Similar Documents

Publication Publication Date Title
CN102405285B (zh) Foxm1肽及包含它的疫苗
CN102333867B (zh) C1orf59肽及包含它的疫苗
US9745343B2 (en) Method of inducing an immune response by administering WDRPUH epitope peptides
WO2010070877A1 (en) Elovl7 epitope peptides and vaccines containing the same
AU2010216980B2 (en) FOXM1 peptides and vaccines containing the same
HK1240953A1 (en) Wdrpuh epitope peptides and vaccines containing the same
HK1165460A (en) Foxm1 peptides and vaccines containing the same
HK1165460B (en) Foxm1 peptides and vaccines containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant